About Complement decay-accelerating factor
Complement decay-accelerating factor (CD55) is a protein
from Homo sapiens identified by UniProt accession
P08174, 381 residues long.
MolForge cross-references it against 0 known binders and
466 disease associations.
Target properties
| Protein name | Complement decay-accelerating factor |
| UniProt accession | P08174 |
| Gene | CD55 |
| Organism | Homo sapiens |
| Length | 381 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (466)
Diseases linked to this target (Open Targets).
- Protein-losing enteropathy · score 0.62
- primary intestinal lymphangiectasia · score 0.46
- refractive error · score 0.38
- blood protein measurement · score 0.33
- Myopia · score 0.33
- refractive error measurement · score 0.31
- self reported educational attainment · score 0.29
- age at onset · score 0.26
- complement decay-accelerating factor measurement · score 0.25
- Hypermetropia · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P08174-F1 | alphafold | PREDICTED | 78.27 | — |
Amino-acid sequence (381 residues)
MTVARPSVPA ALPLLGELPR LLLLVLLCLP AVWGDCGLPP DVPNAQPALE GRTSFPEDTV ITYKCEESFV KIPGEKDSVI CLKGSQWSDI EEFCNRSCEV PTRLNSASLK QPYITQNYFP VGTVVEYECR PGYRREPSLS PKLTCLQNLK WSTAVEFCKK KSCPNPGEIR NGQIDVPGGI LFGATISFSC NTGYKLFGST SSFCLISGSS VQWSDPLPEC REIYCPAPPQ IDNGIIQGER DHYGYRQSVT YACNKGFTMI GEHSIYCTVN NDEGEWSGPP PECRGKSLTS KVPPTVQKPT TVNVPTTEVS PTSQKTTTKT TTPNAQATRS TPVSRTTKHF HETTPNKGSG TTSGTTRLLS GHTCFTLTGL LGTLVTMGLL T
Explore Complement decay-accelerating factor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets